ABSTRACT Seventeen patients with acute transmural myocardial infarction and angiographically confirmed complete coronary occlusion were treated with heparin combined with intravenous singlechain urokinase-type plasminogen activator (scu-PA), obtained by expression of the cDNA encoding mature human scu-PA in Escherichia coli. In eight patients, recombinant scu-PA (rscu-PA) was given as a 10 mg bolus followed by 30 mg over 1 hr. Recanalization was obtained in six patients, but with persistent delayed opacification of the vessel in four of these patients. During infusion, a plateau level of rscu-PA antigen in plasma of 3.4 gtg/ml (median value, range 1.4 to 5.5) was reached. At the end of the infusion the a2-antiplasmin level had decreased to 54% (median, range 22% to 82%) of the preinfusion level, the fibrinogen level to 89% (median, range 26% to 101%), and fibrinogen degradation products (FDPs) to 20 ,g/ml (median, range 8 to 387). In nine patients, rscu-PA was administered as a 10 mg bolus followed by 60 mg over 1 hr. This resulted in recanalization with normal distal filling of the vessel in seven patients, within 46 17 min (mean + SD). During infusion the concentration of rscu-PA in plasma increased to a median value of 7.4 ,ug/ml (range 4.0 to 13.3). At the end of the infusion the a2-antiplasmin level was 22% of baseline (range 5% to 47%), the fibrinogen level 45%
THERE IS increasing evidence that acute myocardial infarction is often associated with coronary artery thrombosis,' that infusion of thrombolytic agents can cause coronary reperfusion in a high proportion of patients,2 and that early coronary thrombolysis may preserve myocardial function' and reduce mortality. 4' Tissue-type plasminogen activator (t-PA), a thrombolytic agent with a high degree of fibrin-selectivity, is an efficient agent for coronary thrombolysis6 with a better therapeutic index and causing less derangement THERAPY AND PREVENTION-CORONARY THROMBOLYSIS expression of the cloned full-length human scu-PA gene in E. coli15 and was provided by Grilnenthal GmbH, Aachen, West Germany. The agent was supplied in vials containing 10 mg rscu-PA in approximately 3 ml of diluent and was kept frozen until use. The purified unglycosylated protein migrated as a single band with a molecular weight of 47,000 on sodium dodecyl sulfate-gel electrophoresis under reducing conditions. It had a specific activity of 175,000 IU/mg as measured on chromogenic substrate (S-2444, Kabi Diagnostica, Stockholm, Sweden) after activation with plasmin. It was devoid of urokinase activity (<0.5%), pyrogens, and acute toxins. The dose to be given intravenously over 1 hr was diluted to 50 ml with saline and was infused with a constant-rate infusion pump.
Patients and study design. Patients with chest pain attributable to myocardial ischemia lasting for at least 30 min and of less than 6 hr duration and with electrocardiographic criteria of acute transmural myocardial infarction were eligible. They were entered into the study after having given their informed consent and after angiographic demonstration of complete occlusion of the infarct-related coronary artery. The patients were anticoagulated with 7500 U of heparin and they received a bolus injection of 10 mg of rscu-PA over 2 volume of a mixture of thrombin (20 U/ml) and aprotinin (100 k1U/ml) to obtain serum for measurements of fibrinogen degradation products (FDPs).'9
Results
Patients. Characteristics of patients entered into the study are summarized in table 1. The patient group consisted of three women and 14 men, ages 34 to 68 years, with a majority of right coronary artery occlusion (9/17 patients). All patients were treated within 6 hr of the onset of symptoms.
Coronary thrombolysis. 40 mg of rscu-PA, one patient had a drop of his fibrinogen level to 26% of baseline whereas the decrease in four of the other seven patients was less than 10%. In the group treated with 70 mg of rscu-PA, four patients showed a severe drop of their fibrinogen level (to below 15% of baseline). In the patients with severe fibrinogen depletion, extensive a2-antiplasmin consumption (decrease to below 25%) and the appearance of high levels of FDPs in serum (173, 387, 467, 1000, and 1034 gg/ml) were observed. These findings taken together are indicative of an overt systemic fibrinolytic state.
Pharmacokinetics of rscu-PA. One minute after a bolus injection of 10 mg of rscu-PA, the plasma level was 4.5 ± 2.5 gg/ml (mean ± SD), corresponding to a distribution volume of 2.6 + 0.9 liters. During infusion of 30 mg over 1 hr, a plateau level of 3.1 1.3 gg/ml was maintained and with 60 mg/hr reached 7.6 ± 3.4 ,gg/ml. After cessation of the infusion the disappearance of rscu-PA antigen from plasma, x(t), could be described by a sum of two exponential terms: x(t)-0.95e-0009t + 0.05e-00'5twith a t/2of 7.9 ± 1.2 and 48 ± 8 min, respectively. The disappearance rate was virtually identical in both groups.
Side effects and follow-up. The infusions of rscu-PA were well tolerated. In the group given 40 mg of rscu-PA, two patients had no reperfusion. These patients also did not respond to a subsequent intracoronary infusion of 20 mg of rscu-PA over 30 min. In the group given 70 mg of rscu-PA, the two patients who did not show recanalization during the intravenous infusion were also given 20 mg over 30 min via the intracoronary route. This resulted in reperfusion toward the end of the infusion in one patient but no recanalization occurred in the other one.
In 10 patients, the evolution during their hospital stay was uneventful. Three patients underwent successful percutaneous transluminal angioplasty but two CIRCULATION The plateau levels of rscu-PA in blood were proportional with the infusion rate, but with a large interindividual variability. After cessation of the infusion, the turnover rates of rscu-PA from plasma were identical in both groups. This indicates that with the infusion rates used, the clearance mechanisms for rscu-PA are not saturated. In addition, the clearance rate of the unglycosylated rscu-PA is very similar to that of natural scu-PA, the bulk of the material being cleared from plasma with a tl/2 of approximately 8 min.
The results of the present study are very similar to those obtained with natural scu-PA.13 Clot-specific coronary thrombolysis is usually obtained, but in a significant number of patients, for reasons that remain to be clarified, infusion of rscu-PA at a high rate is associated with extensive systemic fibrinolytic activation, leading to fibrinogen depletion.
